The impact of long duration spaceflight on the function of plasma cells

G. Spielmann1, J. Campbell1, B.E. Cruclan2, M. Laughlin3 and R.J. Simpson, FACSM4
1 Louisiana State University, Baton Rouge, LA, 70803, USA
2 University of Houston, Houston, TX, 77204, USA
3 NASA Johnson Space Center, Houston, TX, 77058, USA
4 University of Arizona, Tucson, AZ, USA

Abstract

Long duration spaceflights have been associated with profound dysregulation of the immune system, which could jeopardize crew safety and mission success. Recent studies have examined the impact of long-duration spaceflight on specific markers of adaptive and innate immunity, but no study to date has characterized humoral immunity and serological markers of B-cell function. Hence, the aim of this study was to characterize acute and chronic changes in polyclonal Free Light Chains (FLC) and IgM levels in astronauts during and after spaceflight and to correlate FLC levels with serum immunoglobulins (IgA, IgG, IgM), cystatin C and renal function.

Introduction

Astronauts are subjected to increased physical and psychological stressors during long-term spaceflight missions, such as increased radiation exposure, microgravity and disrupted circadian rhythm.

Such Physical and Psychological Stressors are known to be associated with immune dysregulation.

Recent scientific projects entitled “Salivary Markers” (MTL #725) and “Integrated Immune” (SMO-015) were conducted to assess the impact of a 6-month mission on the ISS on aspects of innate and adaptive immune function.

Theses studies however did not characterize humoral immunity and serological markers of B-cell function. Consequently it remains unknown whether spaceflight impacts overall B-cell function, and subsequently expose astronauts to increased risk for infection.

The purpose of this study is to advance the findings from two ISS flight studies (“Integrated Immune” and “Salivary Markers”) by characterizing acute and chronic changes in polyclonal Free Light Chains (FLC), and in Immunoglobulin Ig class switching, indicative of a state of chronic inflammation and overall B-cell function.

Astronauts: A total of 29 Astronauts from NASA and ESA (N “Integrated immune” = 23; N “salivary markers”=6) of various nationalities who spent 6 months in the International Space Station took part in this study. Additionally, samples from 6 ground-based controls from the “Salivary Markers” study were analyzed.

Samples: Salivary Markers: Baseline saliva and salivary samples were taken 5 month before launch and throughout the mission from the 6 Astronauts and their associated ground-based control subjects as described in Figure 1.

Integrated Immune: Baseline plasma samples were taken 5 month before launch from the 23 Astronauts (10 Rookies and 13 Veterans). Additional samples were collected 45 Days before launch, three times during the mission (FD-10 “Early”, FD-90 “Mid” and R-1 “Late”), immediately upon return, and after 30 days back on Earth.

Materials and Methods

ICU Immune Function

Kidney Function: Serum Cystatin C was measured in the stored samples to evaluate renal function in the Astronauts and ground-based controls using Enzyme Linked Immunosorbent Assays.

Immunoglobulin Measurements: Total IgA, IgM and IgG were measured in a total of 150ul of thawed plasma sample from all astronauts and corresponding controls using commercially available ELISA kits.

Plasma and Salivary FLC: Plasma and Saliva samples were thawed and analyzed using Enzyme Linked Immunosorbent Assays (Abingdon Health, Oxford, UK).

Statistical analysis: Multiple, mixed models were utilized throughout this study to evaluate the effect of spaceflight on FLC and Immunoglobulin levels. Significant statistical significance was be set at p≤0.05.

Results

Table 1. Changes in plasma IgA, IgM and IgG in Astronauts and Ground-based Controls before, during and following 6 months in the ISS. (n=23 Astronauts and 6 Controls). Results are presented ± SD. Significant Differences between Pre-flight values (* p<0.05).

Table 1.

<table>
<thead>
<tr>
<th>Days</th>
<th>Pre-flight</th>
<th>Flight</th>
<th>Early</th>
<th>Mid-flight</th>
<th>Return</th>
<th>Late</th>
<th>Return+30</th>
<th>Return+60</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD</td>
<td>112.3 ± 10.8</td>
<td>143.05 ± 10.8</td>
<td>148.87 ± 10.8</td>
<td>143.91 ± 10.8</td>
<td>119.02 ± 10.8</td>
<td>143.91 ± 10.8</td>
<td>148.87 ± 10.8</td>
<td>143.91 ± 10.8</td>
</tr>
</tbody>
</table>

Conclusions

- Plasma IgA concentrations were elevated in astronauts during flight (early, mid-flight and late-flight) when compared to pre-flight values, but no significant difference was observed in plasma IgA in the ground-based controls. Plasma IgM and IgG were elevated in astronauts upon return on Earth (R+18) when compared to pre-flight values.

- Plasma Lambda FLC concentrations were elevated in astronauts during flight (early, mid-flight and late-flight) when compared to post-flight values (R+18). Plasma Kappa FLC concentrations remained stable throughout the mission. After controlling for Astronaut's Experience (first mission vs one or more missions), Rookie astronauts had an increase in plasma Kappa FLC during flight, but not veteran astronauts.

- In-flight Herpesvirus reactivation (CMV, EBV and VZV) did not impact Immunoglobulins and FLC levels in astronauts.

These results suggest that while astronauts who are flying in the ISS for the first time may exhibit greater plasma cell activation than their more experienced counterparts, overall light chains and whole immunoglobulin output from plasma cells appear to be relatively unaffected by long-duration spaceflight, indicating that plasma cell immune competency is maintained in microgravity and risk of infection does not appear to be magnified.

Funding Source: NASA NNJ15ZSA001N-Omnibus to GS.